[Genetic Counselor]

Genetic tests are highly accurate for detecting the specific gene changes they are designed to look for. However, no test is completely without limitations, and results are always interpreted alongside your clinical history and family background by a geneticist to give you the most reliable picture.

[Genetic Counselor]

Inheritance patterns describe how a condition is passed down. In autosomal dominant conditions, one changed gene copy from either parent is enough to cause the condition, however some autosomal dominant conditions are random event that is not inherited from either of the parents. In autosomal recessive conditions, both copies must be changed. In X-linked conditions, the gene is on the X chromosome, which often affects males and females differently. Your geneticist will explain which pattern applies to your specific situation.

[Genetic Counselor]

All hereditary diseases are genetic, but not all genetic diseases are hereditary. A hereditary disease is passed down from parent to child through genes. A genetic disease can also occur from a new, spontaneous gene change that was not inherited from either parent.

[Genetic Counselor]

Many genetic conditions can be managed effectively with the right care plan, even if they cannot be cured. Early diagnosis often allows for better symptom management, informed treatment choices, and access to specialist care suited to the specific condition.

[Genetic Counselor]

A follow-up consultation with an expert should be done to go through the results in detail. This includes what they mean for your health or your child’s health, what steps to take next, and whether other family members should also be tested.

[Genetic Counselor]

Yes. Genetic test results are handled with strict medical confidentiality, just like any other health record, and are shared only with you and the doctors involved in your care.

[Genetic Counselor]

Not necessarily. Inheritance depends on the specific condition and how it is passed down. Some conditions require both parents to carry a gene change, while others involve different patterns. A consultation with an expert can calculate your specific risk and explain your family’s situation clearly.

[Genetic Counselor]

Amniocentesis is a diagnostic prenatal test preformed from 15 weeks of pregnancy onwards to identify genetic disorders. It involves inserting a fine needle through the maternal abdomen into the amniotic sacs, which surrounds and protects the baby, to withdraw a small amount of fluid surrounding the baby. The fluid is called amniotic fluid and contains fetal cells, which are analyzed for chromosomal and, if indicated, specific genetic conditions.

Unlike NIPT or ultrasound markers, amniocentesis provides a definitive diagnosis — it directly examines fetal chromosomes (karyotype/microarray) rather than estimating risk.

It is typically recommended for:

*Women with positive prenatal screening tests such as dual marker, NIPT etc.
*Previous child or previous pregnancy with a genetic disorder
*Advanced maternal age of 35 years or above.
*Significant or multiple ultrasound markers/structural anomalies
*Family history of a genetic condition requiring specific testing
*Couple carrier for a genetic disorder

It is usually performed between 15–20 weeks of gestation and can be done later at any stages of pregnancy if needed. It is not done before 15 weeks due to higher procedure-related risk.

It provides a definitive result rather than a risk estimate and allows parents and clinicians to plan management, further testing, or pregnancy decisions with certainty, rather than probability. The accuracy of these tests are greater than 99%.

Limitations:

Procedure-related miscarriage risk exists, generally cited as approximately 0.1% in experienced hands – this should be discussed with the patient’s own clinician for center-specific and patient health-specific figures.
It is an invasive procedure requiring informed consent and is performed by a trained specialist under ultrasound guidance.
Results (especially full karyotype) can take 1–3 weeks, though rapid FISH/QF-PCR results for common trisomies are often available within 48–72 hours, time taken for report depends on the test performed and can take longer if advanced tests like whole exome sequencing or whole genome sequencing are performed.
It does not detect every possible genetic condition: the specific test ordered (karyotype vs. microarray vs. targeted panel) depending on the provisional diagnosis made or what the screening tests are indicated towards determines what is covered.

[Genetic Counselor]

The retronasal triangle (RT) is an ultrasound view of the fetal face taken in the coronal plane, showing three echogenic (bright) structures: the two frontal processes of the maxilla and the nasal bone, forming a triangular shape behind the nose. It is assessed during first-trimester (11–14 week) or early second-trimester scans.

Absence or abnormality of the retronasal triangle is associated with cleft lip/palate and has also been studied as a soft marker for chromosomal abnormalities, since nasal bone and midface development can be affected in conditions like Trisomy 21.

It’s assessed as part of a detailed NT/anomaly scan performed by a trained sonologist – not a routine finding on a basic dating scan.

An absent retronasal triangle typically prompts closer evaluation of the fetal palate and face, and may be factored into overall chromosomal risk alongside other markers.

Limitations:

*Requires a specific imaging plane and operator expertise which not all centers assesses routinely.
*Isolated absence, especially with an otherwise normal detailed scan, has a lower predictive value than when combined with other findings.

[Genetic Counselor]

NIPT is a blood test done on the mother (usually after 10 weeks of gestation) that analyzes cell-free fetal DNA (cffDNA) circulating in maternal blood. It screens for common chromosomal conditions — primarily Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome) and can also screen for sex chromosome variations.

NIPT has a much higher sensitivity and specificity than traditional biochemical screening (double/quad marker tests) for the common trisomies, with detection rates typically above 99% for Trisomy 21.

Who should care:

*Patients with an abnormal double marker, triple marker, or quad screen
*Patients with soft markers on ultrasound
*Advanced maternal age (35+)
*Anyone wanting a highly sensitive screening option, regardless of background risk

NIPT is typically offered from 10 weeks gestation onward. It’s a screening test, not a replacement for diagnostic testing when a definitive answer is required (e.g., before major medical decisions).

A low-risk NIPT result significantly reduces anxiety and often avoids the need for invasive testing. A high-risk NIPT result prompts a diagnostic test (amniocentesis or CVS) for confirmation before any clinical decision is made.

Limitations:

NIPT is a screening test, not diagnostic — a “high risk” result must be confirmed with amniocentesis or CVS.
False positives and false negatives, while rare, do occur.
It does not screen for all genetic or structural conditions — a normal NIPT does not rule out other issues (e.g., structural anomalies still require ultrasound follow-up).
Placental mosaicism or vanishing twin can occasionally cause discordant results.

[Genetic Counselor]

Soft markers are minor variations seen on a fetal ultrasound that are not structural abnormalities but are statistically associated with a slightly higher chance of chromosomal conditions (such as Down syndrome/Trisomy 21, Trisomy 18, or Trisomy 13). They are not defects — they are subtle sonographic findings that can occur in completely healthy fetuses as well.

Common soft markers include:

Nuchal fold thickening
Echogenic intracardiac focus (EIF)
Echogenic bowel
Mild pyelectasis (renal pelvis dilation)
Shortened femur or humerus length
Choroid plexus cysts
Absent or hypoplastic nasal bone
Absent or hypoplastic retronasal triangle (discussed below)

Soft markers shift risk, they don’t confirm or rule out a condition on their own. A single isolated soft marker in a low-risk pregnancy is usually not significant. Multiple markers, or a marker combined with an already elevated risk (from maternal age, NIPT, or biochemical screening), carries more weight.

Soft marker findings are used to refine existing risk assessments. They often prompt a conversation about further testing (NIPT, amniocentesis) depending on background risk. It usually leads to a follow-up scan, a genetic counseling discussion, and sometimes a recommendation for NIPT or diagnostic testing.

Limitations: Soft markers have low specificity, many normal fetuses show one marker. Their significance depends heavily on gestational age, whether it’s isolated or multiple, and the mother’s baseline risk. They are not diagnostic; they are probabilistic.

[Genetic Counselor]

At 17 weeks, a non-visualized retronasal triangle can imply one of the following, and distinguishing between them requires careful evaluation:

Technical/positional limitation: fetal position, maternal body habitus, or scanning angle can prevent clear visualization even when anatomy is normal. This is the most common reason and is not itself concerning.
Possible cleft lip/palate: since the retronasal triangle view is used specifically to screen for facial clefts, non-visualization warrants a dedicated, detailed facial and palate assessment.
Association with chromosomal anomalies: in some studies, an absent retronasal triangle has been linked to a higher likelihood of Trisomy 21 and other aneuploidies, particularly when seen alongside other soft or hard markers.

What it implies for the fetus:

It does not, by itself, confirm a diagnosis of cleft lip/palate or a chromosomal condition.
It is a prompt for further evaluation, not a conclusion.

This is a good example of why isolated findings should never be interpreted in isolation from the fetus’s full scan and screening history. The clinical significance depends entirely on:

Whether it’s an isolated finding or accompanied by other markers/structural findings
The mother’s background risk (age, prior screening results)
Whether a repeat scan can achieve visualization

Limitations:

*Non-visualization at 17 weeks is later than the ideal window (11–14 weeks) for this specific marker, so its predictive value at this gestation is less standardized in literature compared to first-trimester assessment.
*A single research-based association does not equal individual diagnostic certainty — this is why follow-up imaging and, where indicated, genetic counseling matter more than the marker in isolation.

During first-trimester screening, the fetal nasal bone is assessed as a “soft marker” — a physical feature that, when absent or underdeveloped (hypoplastic), is statistically associated with a higher chance of certain chromosomal conditions, most notably Trisomy 21 (Down syndrome). It’s also occasionally associated with some structural or skeletal conditions, though far less commonly.

A soft marker is not a diagnosis on its own. Many babies with an absent or hypoplastic nasal bone turn out to be chromosomally and structurally completely normal. The finding adjusts a risk estimate usually alongside other markers like NT, blood markers, and maternal age, rather than confirming anything by itself.

Hypoplastic means underdeveloped or smaller than expected for the gestational age. This is different from “absent,” where no nasal bone is visualized at all. Both are grouped together as abnormal findings in many reports, but they’re technically distinct: hypoplastic means the bone is there but under-measured; absent means it isn’t seen.

NT of 2.0mm at 12 weeks 6 days is well within the normal range (the cutoff is typically under 2.5–3.0mm depending on CRL at this gestational age). A normal NT lowers overall concern.
NIPT (non-invasive prenatal testing) analyzes cell-free fetal DNA in maternal blood and has very high sensitivity for Trisomy 21, and high sensitivity for Trisomy 18 and 13. A negative NIPT result substantially lowers the likelihood of these conditions, even when an isolated soft marker like nasal bone hypoplasia is present.

It’s worth understanding that NIPT is a screening test, not a diagnostic one: it estimates probability rather than confirming or ruling out a condition with certainty, and it doesn’t screen for every possible genetic or chromosomal condition. But for the specific conditions nasal bone hypoplasia is most associated with, a negative NIPT is meaningfully reassuring.

Get a detailed anomaly/Level II scan with a maternal-fetal medicine (MFM) specialist, who can directly reassess the nasal bone and check for any other associated structural findings.
Discuss the combined picture- NT, NIPT result, and nasal bone finding with a genetic counselor, who can walk you through an individualized, updated risk assessment rather than a general statistic.
Amniocentesis is a diagnostic option that gives a definitive answer, but given if normal NT and negative NIPT, it is not automatically necessary. The decision is a personal one best made after the detailed scan and counseling – not something you need to decide right away out of fear.

[Genetic Counselor]

Not necessarily. If both parents carry a change in gene causing the same genetic condition, each pregnancy has a 25% chance of the child inheriting the genetic change from both parents and being affected, a 50% chance of the child being a carrier like the parents, and a 25% chance of the child not inheriting the changed gene at all. These odds apply to each individual pregnancy.

[Genetic Counselor]

Babies born with Down syndrome usually undergo a few routine checks in the first days and weeks:

*Heart evaluation (echocardiogram)
*Hearing check
*Thyroid function test
*Check for any digestive tract differences
*A blood test to confirm the diagnosis genetically

Many babies have low muscle tone (hypotonia), which can make feeding slower at first. Lactation support and early physiotherapy referrals help significantly here.

Children with Down syndrome benefit from regular, coordinated check-ups rather than one-off treatment:

*Annual thyroid checks
*Regular vision and hearing checks
*Early speech, occupational, and physical therapy
*Monitoring for sleep apnea and, less commonly, celiac disease

Every child with Down syndrome develops differently. Intellectual disability is usually mild to moderate, and with early intervention, many children go on to attend inclusive schools, build strong communication skills, and live independent, fulfilling lives as adults.

[Genetic Counselor]

Non-Invasive Prenatal Testing (NIPT) analyzes small fragments of fetal DNA circulating in the mother’s blood to screen for common chromosomal conditions (such as Down syndrome) starting from around the 10th week of pregnancy. It’s a screening test, not diagnostic – meaning a high-risk result would typically be followed up with a diagnostic test like amniocentesis or CVS (chorionic villus sampling), which directly samples fetal tissue for confirmation.

[Author]

Posts